The COVID-19 vaccine: A race nearing the finish line
The impact of the coronavirus disease-2019 (COVID-19) pandemic on global health and the economy is so extensive that it has driven several countries to go on a quest for a vaccine. The evaluation of future generation vaccine platforms is the need of the hour. In the majority of nations, innovative t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=2;spage=111;epage=121;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410964571553792 |
|---|---|
| author | Tarun Kumar Suvvari Siddhi Hegde Shreya Sreeram L V Simhachalam Kutikuppala |
| author_facet | Tarun Kumar Suvvari Siddhi Hegde Shreya Sreeram L V Simhachalam Kutikuppala |
| author_sort | Tarun Kumar Suvvari |
| collection | DOAJ |
| description | The impact of the coronavirus disease-2019 (COVID-19) pandemic on global health and the economy is so extensive that it has driven several countries to go on a quest for a vaccine. The evaluation of future generation vaccine platforms is the need of the hour. In the majority of nations, innovative technology is being used to hasten the vaccine development process. The evolution of a safe and effective vaccine takes time. The journey from its genesis to making the final product available to the public is a tedious course of action. Vaccines generally function by mimicking the infectious agent, which can be a bacterium, virus, or other microorganisms that cause disease. The characteristic feature of the COVID-19 vaccine development is the use of a wide array of technology platforms, including the virus-like particle, peptide, nucleic acid (DNA and RNA), viral vector (replicating and nonreplicating), live attenuated virus, an inactivated virus, and recombinant protein in the process of vaccine preparation. Despite the hurried nature of their current development, all COVID-19 vaccines being developed will receive regulatory approval only if they meet the rigorous safety and efficacy standards. Effective and productive global co-ordination and co-operation between the vaccine developing agencies, regulating authorities, policymakers, governments, funding organizations, and public health bodies are essential to ensure the large-scale manufacturing and equitable distribution of promising end-stage vaccine candidates. Besides various concerns on the safety and efficacy of various COVID-19 vaccines, the vaccination drive had successfully started in most developed and developing countries in the global race to vaccinate the people. |
| format | Article |
| id | doaj-art-60f5aed0ba1a4ece83cfa30c0c26fbf6 |
| institution | Kabale University |
| issn | 0976-0016 2213-3682 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Apollo Medicine |
| spelling | doaj-art-60f5aed0ba1a4ece83cfa30c0c26fbf62025-08-20T03:34:56ZengSAGE PublishingApollo Medicine0976-00162213-36822021-01-0118211112110.4103/am.am_18_21The COVID-19 vaccine: A race nearing the finish lineTarun Kumar SuvvariSiddhi HegdeShreya SreeramL V Simhachalam KutikuppalaThe impact of the coronavirus disease-2019 (COVID-19) pandemic on global health and the economy is so extensive that it has driven several countries to go on a quest for a vaccine. The evaluation of future generation vaccine platforms is the need of the hour. In the majority of nations, innovative technology is being used to hasten the vaccine development process. The evolution of a safe and effective vaccine takes time. The journey from its genesis to making the final product available to the public is a tedious course of action. Vaccines generally function by mimicking the infectious agent, which can be a bacterium, virus, or other microorganisms that cause disease. The characteristic feature of the COVID-19 vaccine development is the use of a wide array of technology platforms, including the virus-like particle, peptide, nucleic acid (DNA and RNA), viral vector (replicating and nonreplicating), live attenuated virus, an inactivated virus, and recombinant protein in the process of vaccine preparation. Despite the hurried nature of their current development, all COVID-19 vaccines being developed will receive regulatory approval only if they meet the rigorous safety and efficacy standards. Effective and productive global co-ordination and co-operation between the vaccine developing agencies, regulating authorities, policymakers, governments, funding organizations, and public health bodies are essential to ensure the large-scale manufacturing and equitable distribution of promising end-stage vaccine candidates. Besides various concerns on the safety and efficacy of various COVID-19 vaccines, the vaccination drive had successfully started in most developed and developing countries in the global race to vaccinate the people.http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=2;spage=111;epage=121;aulast=coronavirus disease-2019efficacypandemicsevere acute respiratory syndrome coronavirus 2vaccine |
| spellingShingle | Tarun Kumar Suvvari Siddhi Hegde Shreya Sreeram L V Simhachalam Kutikuppala The COVID-19 vaccine: A race nearing the finish line Apollo Medicine coronavirus disease-2019 efficacy pandemic severe acute respiratory syndrome coronavirus 2 vaccine |
| title | The COVID-19 vaccine: A race nearing the finish line |
| title_full | The COVID-19 vaccine: A race nearing the finish line |
| title_fullStr | The COVID-19 vaccine: A race nearing the finish line |
| title_full_unstemmed | The COVID-19 vaccine: A race nearing the finish line |
| title_short | The COVID-19 vaccine: A race nearing the finish line |
| title_sort | covid 19 vaccine a race nearing the finish line |
| topic | coronavirus disease-2019 efficacy pandemic severe acute respiratory syndrome coronavirus 2 vaccine |
| url | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=2;spage=111;epage=121;aulast= |
| work_keys_str_mv | AT tarunkumarsuvvari thecovid19vaccinearacenearingthefinishline AT siddhihegde thecovid19vaccinearacenearingthefinishline AT shreyasreeram thecovid19vaccinearacenearingthefinishline AT lvsimhachalamkutikuppala thecovid19vaccinearacenearingthefinishline AT tarunkumarsuvvari covid19vaccinearacenearingthefinishline AT siddhihegde covid19vaccinearacenearingthefinishline AT shreyasreeram covid19vaccinearacenearingthefinishline AT lvsimhachalamkutikuppala covid19vaccinearacenearingthefinishline |